The Educational Programmes on this page cover the following items:
Understanding the changing treatment landscape in HCC
Dr. Richard Finn, Dr. Amit Singal and Dr. Catherine Frenette discuss the topic ‘Understanding the changing treatment landscape in HCC and optimising therapy for the individual patient’. Please click on the link to watch the video and download the slides.
Update of EASL guidelines on management of HCC 2018
Dr. Catherine Frenette discusses the recently updated EASL clinical practice guidelines on the management of hepatocellular carcinoma (HCC).
HCC highlights from EASL 2017
HCC CONNECT Update from…
HCC CONNECT Update from ESMO 2018
HCC CONNECT has summarised the highlights from ESMO 2018 for you
AASLD & ILCA 2017
HCC CONNECT Update from Seoul and Washington DC
HCC CONNECT has summarised the highlights of ILCA 2017 and AASLD 2017.
A CONNECT Update from Madrid
HCC CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.
HCC CONNECT Update from Amsterdam
HCC CONNECT has summarised the highlights of EASL 2017 for you.
Your clinical questions answered
Please submit your clinical topic for the next HCC CONNECT newsletter here.
Is there a difference in liver cancer rates in patients who receive treatment for hepatitis?
Dr. Sammy Saab discusses the clinical question: Is there a difference in liver cancer rates in patients who receive treatment for hepatitits?
What is the best approach for trans-arterial therapy in HCC?
Dr. Alexander Kim discusses the clinical question: What is the best approach for trans-arterial therapy in HCC?
Relevant papers discussed
Sequential sorafenib and regorafenib in patients with advanced HCC
Dr. Mohamed Bouattour discusses the recently published additional analyses from the phase 3 RESORCE trial on sequential treatment with sorafenib followed by regorafenib for hepatocellular carcinoma.
SIRT or sorafenib in patients with locally advanced HCC: SARAH and SIRveNIB trials
Dr. Mohamed Bouattour from Hôpital Beaujon, APHP Clichy, France, discusses the SARAH and SIRveNIB trials in locally advanced HCC